

## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

### Health Technology Appraisal (MTA)

#### Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90)

#### Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Boehringer-Ingelheim (dipyridamole)</li> <li>• Bristol-Myers Squibb Pharmaceuticals and Sanofi-Aventis [joint marketing authorisation] (clopidogrel)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action Heart</li> <li>• Afiya Trust</li> <li>• Age Concern England</li> <li>• Anticoagulation Europe(ACE)</li> <li>• Arrhythmia Alliance</li> <li>• Black Health Agency</li> <li>• British Cardiac Patients Association</li> <li>• Cardiac Risk in the Young (CRY)</li> <li>• Cardiomyopathy Association</li> <li>• Chinese National Healthy Living Centre</li> <li>• Confederation of Indian Organisations</li> <li>• Counsel and Care</li> <li>• Different Strokes</li> <li>• Equalities National Council</li> <li>• Heart Care Partnership (UK)</li> <li>• HEART UK</li> <li>• Help the Aged</li> <li>• Muslim Council of Great Britain</li> <li>• Muslim Health Network</li> <li>• Neurological Alliance</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Stroke Association</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Age Concern Cymru</li> <li>• Board of Community Health Councils in Wales</li> <li>• British Cardiovascular Industry Association</li> <li>• British National Formulary</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Public Health Service for Wales</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• NHS Purchasing and Supplies Agency</li> <li>• NHS Quality Improvement Scotland</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Actavis UK (aspirin)</li> <li>• Alliance Pharmaceuticals (aspirin)</li> <li>• Arrow Generics (aspirin)</li> <li>• Ashbourne Pharmaceuticals (aspirin)</li> <li>• Aspar Pharmaceuticals (aspirin)</li> <li>• Bayer (aspirin)</li> <li>• C P Pharmaceuticals (aspirin)</li> <li>• Dexcel-Pharma (aspirin)</li> <li>• Focus Pharmaceuticals (aspirin)</li> <li>• Galpharm-International (aspirin)</li> </ul>

National Institute for Health and Clinical Excellence

Provisional matrix for the appraisal of Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90)

Issue date: May 2009

## Appendix B

Consultees	Commentators (no right to submit or appeal)
<p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of British Neurologists</li> <li>• British Association for Nursing in Cardiac Care</li> <li>• British Association for Service to the Elderly</li> <li>• British Association of Stroke Physicians</li> <li>• British Cardiovascular Intervention Society (BCIS)</li> <li>• British Cardiovascular Society</li> <li>• British Geriatrics Society</li> <li>• British Heart Foundation</li> <li>• British Society for Haematology</li> <li>• British Society for Heart Failure</li> <li>• Clinical Leaders in Thrombosis (CLOT)</li> <li>• Heart Rhythm UK</li> <li>• National Heart Forum (UK)</li> <li>• Primary Care Cardiovascular Society</li> <li>• Primary Care Neurology Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians Cardiology Committee</li> <li>• Royal Society of Medicine – Intellectual Disabilities Forum</li> <li>• Society for Cardiological Science &amp; Technology</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• Vascular Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Barnsley PCT</li> <li>• Brent PCT</li> <li>• Department of Health</li> <li>• Welsh Assembly Government</li> </ul>	<ul style="list-style-type: none"> <li>• Generics UK (aspirin)</li> <li>• Genus Pharmaceuticals (aspirin)</li> <li>• IVAX Pharmaceuticals UK (aspirin)</li> <li>• Kent Pharmaceuticals (aspirin)</li> <li>• Napp Pharmaceuticals (aspirin)</li> <li>• Pinewood Healthcare (aspirin)</li> <li>• Reckitt Benckiser (aspirin)</li> <li>• Sandoz (aspirin)</li> <li>• Sterwin Medicines (aspirin)</li> <li>• Teva UK (aspirin)</li> <li>• The Boots Company (aspirin)</li> <li>• Thornton &amp; Ross (aspirin)</li> <li>• Wockhardt UK (aspirin)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Society for Cardiovascular Research [BCS affiliated]</li> <li>• Cardiovascular Diseases Specialist Library (CVDSL)</li> <li>• Central Cardiac Audit Database</li> <li>• Cochrane Heart Group</li> <li>• Cochrane Peripheral Vascular Diseases Group</li> <li>• Cochrane Stroke Group</li> <li>• CORDA</li> <li>• National Institute for Health Research</li> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Research Institute for the Care of Older People</li> <li>• United Kingdom Clinical Research Network</li> <li>• Wellcome Trust - Cardiovascular Research Initiative</li> </ul> <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> <li>• Liverpool Reviews &amp; Implementation Group, University of Liverpool</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul>

National Institute for Health and Clinical Excellence

Provisional matrix for the appraisal of Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90)

Issue date: May 2009

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
	<u>Associated Guideline Groups</u> <ul style="list-style-type: none"> <li>• National Clinical Guideline Centre for Acute and Chronic Conditions</li> </ul> <u>Associated Public Health Groups</u> <ul style="list-style-type: none"> <li>• None</li> </ul>

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

**Definitions:**

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the National Institute for Health and Clinical Excellence

Provisional matrix for the appraisal of Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90)

Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

### Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

National Institute for Health and Clinical Excellence

Provisional matrix for the appraisal of Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90)

Issue date: May 2009